RxDoctor Payments Data

Ruby Jane Sia, MD

Internal Medicine · Apple Valley, CANPI 1518061860

Payments from drug & device makers

$8,392in general payments, 2019–2025

Across 386 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Corcept Therapeutics$723
  • Abbott$668
  • Lilly USA, LLC$606
  • Amgen$487
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,386100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,392 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$49,296
Medicare patients
134
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol79$61,924
OzempicSemaglutide68$59,958
MounjaroTirzepatide52$57,461
EliquisApixaban74$55,474
TrulicityDulaglutide30$36,191
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$31,918
XareltoRivaroxaban32$29,014
CreonLipase/Protease/Amylase12$28,279
LinzessLinaclotide39$26,520
RybelsusSemaglutide23$26,352
OxycontinOxycodone Hcl21$26,266
UbrelvyUbrogepant19$18,577
DapagliflozinDapagliflozin Propanediol34$16,129
Breo ElliptaFluticasone/Vilanterol22$14,173
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$13,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$606$93,65282 claims
Novo NordiskOzempic, Rybelsus$265$86,30991 claims
AbbVieCreon, Linzess, Ubrelvy$1,295$73,37670 claims
AstraZenecaFarxiga$1,214$61,92479 claims
PfizerEliquis, Premarin$388$59,75589 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$442$55,11691 claims
Johnson & JohnsonXarelto$134$29,01432 claims
MerckJanuvia$75$10,41512 claims
Boehringer IngelheimJardiance$127$8,13215 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$76$6,36114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →